Protagonist Therapeutics (PTGX) Gross Profit: 2017-2025
Historic Gross Profit for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to $4.7 million.
- Protagonist Therapeutics' Gross Profit rose 0.79% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.6 million, marking a year-over-year decrease of 35.12%. This contributed to the annual value of $434.4 million for FY2024, which is 624.05% up from last year.
- Latest data reveals that Protagonist Therapeutics reported Gross Profit of $4.7 million as of Q3 2025, which was down 15.04% from $5.5 million recorded in Q2 2025.
- Over the past 5 years, Protagonist Therapeutics' Gross Profit peaked at $255.0 million during Q1 2024, and registered a low of -$19,000 during Q4 2022.
- Over the past 3 years, Protagonist Therapeutics' median Gross Profit value was $16.9 million (recorded in 2025), while the average stood at $64.7 million.
- In the last 5 years, Protagonist Therapeutics' Gross Profit slumped by 100.22% in 2022 and then soared by 263,257.89% in 2023.
- Protagonist Therapeutics' Gross Profit (Quarterly) stood at $8.6 million in 2021, then crashed by 100.22% to -$19,000 in 2022, then skyrocketed by 263,257.89% to $50.0 million in 2023, then skyrocketed by 230.00% to $165.0 million in 2024, then rose by 0.79% to $4.7 million in 2025.
- Its last three reported values are $4.7 million in Q3 2025, $5.5 million for Q2 2025, and $28.3 million during Q1 2025.